El­e­ment Bio­sciences logs 100 DNA se­quencer or­ders as it gains mo­men­tum in a com­pet­i­tive mar­ket

El­e­ment Bio­sciences has re­port­ed 100 com­mer­cial or­ders of its bench­top DNA se­quencer, a fig­ure that out­side ob­servers called sol­id progress as the start­up com­petes for cus­tomers in a mar­ket dom­i­nat­ed by Il­lu­mi­na.

Mol­ly He, El­e­ment’s CEO, said the ma­jor­i­ty of the or­ders have al­ready been shipped, and El­e­ment plans to get the rest out by the end of the year. El­e­ment has cus­tomers in the US and 13 oth­er coun­tries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.